GELITA Unveils Cutting-Edge Excipients at BIO International 2025 in Boston

GELITA Shines at BIO International 2025



GELITA, a prominent name in the field of pharmaceutical gelatin and collagen peptide innovations, is set to showcase its latest advancements at the BIO International conference taking place in Boston in June 2025. The company takes pride in its offerings, with a strong focus on its standout products: MEDELLAPRO® and VACCIPRO®, which specifically cater to the evolving needs of advanced pharmaceutical preparations and medical devices.

The Importance of Excipients in Modern Medicine



In the fast-paced world of pharmaceuticals, excipients—substances used as carriers for the active ingredients of a medication—play a crucial role. GELITA’s ECE portfolio includes options like MEDELLAPRO® and VACCIPRO®, designed to meet the stringent requirements of various medical applications, including vaccine stabilization, tissue engineering, 3D bioprinting, implants, and advanced wound care. Ensuring endotoxin control is vital to guarantee both product safety and patient health, which is precisely what these excipients provide.

MEDELLAPRO®: Versatile and Biocompatible



MEDELLAPRO® is recognized for its exceptional versatility and biocompatibility. It serves a multitude of applications, making it an ideal ingredient for surgical sealants, hemostatic agents, scaffolds for tissue engineering, 3D bioprinting, and drug delivery systems. By incorporating MEDELLAPRO®, developers can create safer and more effective medical products, enhancing patient care and treatment outcomes.

VACCIPRO®: The Gold Standard for Vaccines



On the other hand, VACCIPRO® has emerged as the global gold standard among vaccine manufacturers. Its ability to stabilize vaccines ensures they maintain their effectiveness, exhibiting low allergenic potential and providing high bioavailability with excellent tissue affinity. These attributes make VACCIPRO® a top choice for developers looking to craft safer vaccines that can be reliably administered to patients.

GELITA's Commitment to Innovation and Quality



With a strong emphasis on quality and innovation, GELITA is dedicated to empowering the pharmaceutical and medical device sectors. The company is not only focused on providing effective solutions but is also committed to sustainability. GELITA is advancing its research into biotechnological processes, striving to create animal-free alternatives that possess optimized features, ensuring a more resource-efficient and environmentally friendly approach compared to traditional methods.

The Future of Pharmaceutical Development



Utilizing the expertise housed within the GELITA Pharma Institute and the Biotech RD Hub, GELITA is elaborately planning to broaden its biotechnological capabilities and expand its product portfolio. This is essential for keeping pace with the industry's rapid evolution while consistently meeting the needs of customers.

Visit GELITA at BIO International 2025



Attendees of BIO International are encouraged to visit GELITA at Booth 2865-01, located within the German Pavilion. Here, visitors can explore how MEDELLAPRO® and VACCIPRO® are shaping the future of both vaccine development and medical devices. It promises to be an enlightening experience, showcasing the critical role these innovative excipients play in healthcare solutions.

About GELITA



GELITA stands as one of the leading manufacturers of collagen proteins, headquartered in Eberbach, Germany. With over 150 years of experience, GELITA is committed to innovation, providing high-quality products and comprehensive expertise to customers worldwide. With more than 20 facilities and a global network of experts, GELITA ensures cutting-edge solutions are always on hand for client needs.

GELITA continues to expand its portfolio of collagen proteins, which are increasingly vital across numerous markets, including food, pharmaceuticals, and health nutrition. In a landscape where consumer demands grow increasingly complex, GELITA remains steadfast, delivering natural, healthy, and non-allergenic ingredients that meet the needs of manufacturers and consumers alike.

For more details on GELITA’s products and initiatives, please reach out to their media contacts for further information.

Media Contact


Amy Maggio
Email: [email protected]
Phone: 312-617-6248

Company Contact


Martin Junginger
Senior Expert Global Category Management Pharma Bioscience
GELITA AG
Phone: +49 6271 84 2103
Email: [email protected]

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.